Skip to content

Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study

Detection of Chlamydia DNA by Polymerase Chain Reaction ( PCR ) in Tumours Tissue of Primary Tubal and Ovarian Cancers : a Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02343510
Enrollment
70
Registered
2015-01-22
Start date
2015-01-31
Completion date
2017-03-31
Last updated
2017-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm of Fallopian Tube

Keywords

Fallopian tubal cancer, high grade serous , ovarian cancer

Brief summary

PCR for chlamydia DNA is done in paraffin blocks of cases of primary tubal cancer and is compared to cases of high grade serous ovarian cancer and normal tubes .

Detailed description

The investigators shall review the early cancer detection unite pathology records for the past 10 years , for cases diagnosed with primary Fallopian tube cancers , cases of high and low grade serous ovarian cancer and cases underwent hysterectomy and salpingectomy for non oncological reasons. Paraffin blocks for suitable selected patients will be examined histologically to confirm the primary diagnosis . Chlamydia DNA in these paraffin blocks of the Fallopian tubes and ovarian tissues will be examined using PCR techniques . The possible correlation between the presence of Chlamydia DNA and the ovarian serous tumours and primary tubal cancer will be analyzed statistically .

Interventions

OTHERPCR for chlamydia DNA in primary tubal cancer

PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* any patient with primary tubal cancer and high grade serous cancer and normal tubes.

Exclusion criteria

* clinical pelvic inflammatory disease * salpingectomy for ectopic

Design outcomes

Primary

MeasureTime frame
Presence of chlamydia DNA in tubal and ovarian tissuesUp to 24 weeks

Secondary

MeasureTime frame
Presence of concomitant tubal cancer with high grade serous ovarian cancerUp to 8 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026